Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Non-Standardized Food Allergenic Extract [EPC]
Fraxinus Latifolia Whole is a non-standardized plant allergenic extract used for the diagnosis and treatment of Oregon Ash pollen allergies through skin testing and subcutaneous immunotherapy.
Name
Fraxinus Latifolia Whole
Raw Name
FRAXINUS LATIFOLIA WHOLE
Category
Non-Standardized Food Allergenic Extract [EPC]
Drug Count
6
Variant Count
6
Last Verified
February 17, 2026
About Fraxinus Latifolia Whole
Fraxinus Latifolia Whole is a non-standardized plant allergenic extract used for the diagnosis and treatment of Oregon Ash pollen allergies through skin testing and subcutaneous immunotherapy.
Detailed information about Fraxinus Latifolia Whole
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Fraxinus Latifolia Whole.
As a non-standardized extract, Fraxinus Latifolia Whole does not have a defined potency unit (such as Bioequivalent Allergy Units or BAU) assigned by the FDA. Instead, its strength is typically expressed in terms of weight/volume (w/v) ratios or Protein Nitrogen Units (PNU). The drug belongs to a broad class of allergenic extracts that include Non-Standardized Pollen, Fungal, and Plant extracts. While the prompt mentions classifications like Adrenocorticotropic Hormone [EPC], it is critical to note that in clinical practice, Fraxinus Latifolia is strictly an immunotherapeutic agent and does not possess hormonal activity. The FDA has regulated these extracts under the Center for Biologics Evaluation and Research (CBER) for decades, maintaining their availability for specialized allergy practice despite the lack of modern standardization for every individual plant species.
The mechanism of action for Fraxinus Latifolia Whole is dual-phased, serving both diagnostic and therapeutic functions. At the molecular level, the extract contains complex glycoproteins that act as allergens. When used for diagnostic skin testing (prick or intradermal), these allergens cross-link specific Immunoglobulin E (IgE) antibodies bound to the surface of mast cells and basophils in the skin. This cross-linking triggers degranulation, releasing histamine and other inflammatory mediators, which results in a localized 'wheal and flare' reaction. This reaction allows healthcare providers to confirm a patient's sensitivity to Oregon Ash.
In the context of Allergen Immunotherapy (AIT), the mechanism is more complex and involves the induction of immune tolerance. Repeated, escalating subcutaneous injections of Fraxinus Latifolia Whole shift the patient's immune response from a Th2-dominated profile (which promotes IgE production and allergic inflammation) to a Th1-dominated or T-regulatory (Treg) response. This process leads to the production of 'blocking antibodies,' specifically IgG4, which compete with IgE for allergen binding. Over time, this reduces the activation of mast cells and basophils upon natural exposure to Oregon Ash pollen, effectively desensitizing the patient and providing long-term symptomatic relief.
Unlike traditional small-molecule drugs, the pharmacokinetics of allergenic extracts like Fraxinus Latifolia Whole do not follow standard absorption, distribution, metabolism, and excretion (ADME) patterns involving cytochrome P450 enzymes.
Fraxinus Latifolia Whole is indicated for the following clinical applications:
Fraxinus Latifolia Whole is primarily available in the following dosage forms:
> Important: Only your healthcare provider can determine if Fraxinus Latifolia Whole is right for your specific condition. Immunotherapy should only be conducted under the supervision of a physician trained in the management of systemic anaphylaxis.
Dosage for Fraxinus Latifolia Whole is highly individualized and must be determined by a specialist (allergist or immunologist) based on the patient's sensitivity level.
Fraxinus Latifolia Whole is used in children, but the dosage must be approached with extreme caution. Children are generally started at the same or lower dilutions as adults. Pediatric patients may be at a higher risk for systemic reactions if they have poorly controlled asthma. There is no specific age cutoff, but immunotherapy is rarely initiated in children under the age of 5 due to the difficulty of monitoring for early signs of anaphylaxis.
No specific dosage adjustments are required for patients with renal impairment, as the extract is not cleared by the kidneys. However, the patient's overall health should be stable before administration.
No dosage adjustments are necessary for hepatic impairment. The metabolic processing of allergenic proteins does not involve hepatic CYP450 pathways.
Caution is advised in elderly patients, particularly those with underlying cardiovascular disease. The use of epinephrine (required to treat potential anaphylaxis) may be more dangerous in this population. Healthcare providers may choose more conservative build-up schedules.
If a dose is missed during the build-up phase, the next dose may need to be reduced or the previous dose repeated, depending on the length of the delay. If a maintenance dose is missed for more than 4–6 weeks, the dose is typically reduced to ensure safety. Your allergist will follow a specific 'gap protocol' to resume treatment.
An 'overdose' in the context of allergenic extracts refers to the administration of a dose higher than the patient's current tolerance level. Signs include:
In the event of an overdose or systemic reaction, emergency measures including the administration of epinephrine, antihistamines, and corticosteroids must be initiated immediately.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not attempt to self-administer these injections at home.
Local reactions at the site of injection are the most frequent side effects associated with Fraxinus Latifolia Whole. These are generally considered a normal part of the immune system's response to the allergen.
Systemic reactions are the most significant risk of Fraxinus Latifolia Whole. These can escalate to life-threatening anaphylaxis within minutes.
> Warning: Stop taking Fraxinus Latifolia Whole and call your doctor immediately or seek emergency care if you experience any of these:
With prolonged use (3–5 years of immunotherapy), the primary 'side effect' is the intended desensitization. However, some patients may develop new sensitivities to other allergens over time, though this is generally not attributed to the Fraxinus Latifolia extract itself. There is no evidence that long-term use of allergenic extracts causes autoimmune disease or chronic organ damage.
Fraxinus Latifolia Whole, like all allergenic extracts, carries a significant warning regarding the risk of severe systemic reactions. While not always formatted as a 'Black Box' in the same way as oral medications, the FDA-approved labeling for allergenic extracts mandates prominent warnings stating:
Report any unusual symptoms to your healthcare provider immediately.
Fraxinus Latifolia Whole is a potent biological product. Safety depends on accurate dosing, proper administration technique, and rigorous patient monitoring. It is not a 'vaccine' in the traditional sense and requires a multi-year commitment for efficacy. Patients must be in their baseline state of health on the day of the injection; if you are suffering from an acute infection, fever, or an asthma flare-up, the injection should be postponed.
No FDA black box warnings for Fraxinus Latifolia Whole specifically exist in the traditional 'boxed' format used for pharmaceuticals, but the Standardized Warning for Allergenic Extracts is equivalent in severity. It emphasizes that extracts may cause severe systemic reactions, including anaphylactic shock and death. It also mandates that the extract only be used by physicians who are exceptionally familiar with the product and have the necessary facilities, equipment, and medication (epinephrine) to treat anaphylaxis.
Fraxinus Latifolia Whole generally does not cause sedation. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive or operate machinery until they have fully recovered and been cleared by a physician.
Alcohol should be avoided on the day of the injection. Alcohol can increase blood flow to the skin and potentially accelerate the absorption of the allergen, increasing the risk of a systemic reaction. It may also mask early symptoms of anaphylaxis.
Immunotherapy is typically discontinued after 3 to 5 years of successful treatment. There is no 'withdrawal syndrome,' but stopping prematurely may result in the return of allergy symptoms. If treatment is stopped due to a severe reaction, a thorough risk-benefit analysis must be performed before restarting.
> Important: Discuss all your medical conditions, especially asthma and heart problems, with your healthcare provider before starting Fraxinus Latifolia Whole.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially any heart or blood pressure medications.
Fraxinus Latifolia Whole must NEVER be used in the following circumstances:
Conditions requiring careful risk-benefit analysis include:
Patients allergic to Oregon Ash (Fraxinus latifolia) often show cross-sensitivity to other members of the Oleaceae family. This includes:
If a patient is highly sensitive to one of these, they may react more strongly to the Fraxinus Latifolia Whole extract.
> Important: Your healthcare provider will evaluate your complete medical history, including heart and lung health, before prescribing Fraxinus Latifolia Whole.
Fraxinus Latifolia Whole is classified as FDA Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. The primary risk is not direct fetal toxicity from the extract, but rather the risk of systemic anaphylaxis in the mother, which can lead to uterine contractions, placental abruption, or fetal hypoxia.
It is generally considered safe to continue Fraxinus Latifolia Whole immunotherapy while breastfeeding. The allergenic proteins are not expected to pass into breast milk in any significant quantity, and there is no evidence of harm to the nursing infant. The benefits of controlling the mother's allergic asthma or rhinitis often outweigh the minimal risks.
Immunotherapy is effective in children for preventing the progression of allergic rhinitis to asthma (the 'allergic march'). However, children under age 5 may have difficulty communicating the early symptoms of a systemic reaction (such as an itchy throat or 'funny feeling'). Therefore, the decision to use Fraxinus Latifolia Whole in young children must be made with extreme caution and specialized supervision.
In patients over 65, the risk of comorbid conditions (heart disease, COPD) is higher. Geriatric patients are also more likely to be taking medications like beta-blockers or ACE inhibitors that complicate the management of anaphylaxis. Dose escalation should be more conservative in this population, and a baseline EKG may be recommended.
No specific adjustments are needed. The proteins in Fraxinus Latifolia Whole are broken down into amino acids and do not rely on renal filtration for clearance. However, patients with end-stage renal disease (ESRD) may have altered immune responses and should be monitored closely for unusual reactions.
No dosage adjustments are required. Hepatic function does not affect the processing of subcutaneous allergenic extracts. However, severe liver disease may affect the body's ability to recover from systemic stress, so caution is warranted.
> Important: Special populations require individualized medical assessment and often a more conservative approach to dosing.
Fraxinus Latifolia Whole works through the modulation of the adaptive immune system. The extract contains specific 'Major Allergens' (such as Fra e 1, a common ash pollen protein).
| Parameter | Value |
|---|---|
| Bioavailability | N/A (Subcutaneous administration) |
| Protein Binding | Primarily processed by dendritic cells |
| Half-life | Proteins degraded within hours/days at injection site |
| Tmax | Local peak concentration within 15-30 mins |
| Metabolism | Proteolytic degradation in lymphatic system |
| Excretion | Not renally excreted as intact drug |
Fraxinus Latifolia Whole is classified as a Non-Standardized Plant Allergenic Extract. It belongs to the therapeutic category of Allergen Immunotherapy (AIT). It is distinct from standardized extracts (like Grass or Ragweed) because its potency is not measured against a national reference standard by the FDA.
Common questions about Fraxinus Latifolia Whole
Fraxinus Latifolia Whole is an allergenic extract used specifically for the diagnosis and treatment of allergies to the Oregon Ash tree. In diagnostic settings, it is applied during skin prick testing to see if a patient develops a 'wheal and flare' reaction, indicating a sensitivity. For treatment, it is used in 'allergy shots' (immunotherapy) to help the body build up a tolerance to ash pollen. This is particularly helpful for patients in the Pacific Northwest where the Oregon Ash is prevalent. The goal is to reduce symptoms like sneezing, itchy eyes, and asthma flares during the spring pollination season.
The most common side effects are localized to the area where the injection or skin test was performed. Most patients experience some degree of redness, itching, and swelling at the injection site, which usually resolves within 24 to 48 hours. Some people may also experience a 'late-phase' reaction where the swelling increases several hours after the shot. These local reactions are generally not dangerous but should be reported to your doctor so they can adjust your next dose if necessary. Systemic symptoms like mild tiredness or a temporary increase in hay fever symptoms are also relatively common.
It is strongly recommended that you avoid alcohol on the days you receive an injection of Fraxinus Latifolia Whole. Alcohol can cause blood vessels to dilate (expand), which may speed up the absorption of the allergen into your bloodstream, potentially increasing the risk of a systemic allergic reaction. Furthermore, being under the influence of alcohol can make it difficult for you to notice or accurately describe the early warning signs of anaphylaxis. To ensure maximum safety, wait at least 24 hours after your injection before consuming alcoholic beverages. Always follow the specific safety protocols provided by your allergy clinic.
The safety of Fraxinus Latifolia Whole during pregnancy is a complex issue that requires a consultation with your allergist. Generally, doctors will not start a new course of immunotherapy during pregnancy because of the risk of a severe allergic reaction, which could harm the fetus by reducing oxygen supply. However, if you are already on a stable 'maintenance dose' and are tolerating the shots well, your doctor may decide to continue the treatment throughout your pregnancy. They will usually keep the dose the same or even lower it slightly to prioritize safety. The primary goal is to avoid any systemic reactions while you are pregnant.
Immunotherapy with Fraxinus Latifolia Whole is not an immediate fix for allergy symptoms. Most patients enter a 'build-up phase' that lasts 3 to 6 months, during which the dose is gradually increased. You may not notice any significant improvement in your symptoms during this initial period. Most people begin to feel better during their first or second allergy season after reaching the maintenance dose. For the best long-term results, the treatment is usually continued for 3 to 5 years. This duration helps ensure that the immune system remains desensitized even after the shots are stopped.
Yes, you can stop taking Fraxinus Latifolia Whole injections at any time without experiencing physical withdrawal symptoms, as it is not an addictive medication. However, stopping the treatment before the recommended 3-to-5-year course is finished often means that your allergy symptoms will eventually return. If you stop because you are moving or having side effects, talk to your allergist first. They may be able to transfer your records to a new doctor or adjust your dose to make the treatment more tolerable. Sudden discontinuation simply halts the process of building immune tolerance.
If you miss a scheduled injection of Fraxinus Latifolia Whole, do not try to 'double up' or take an extra dose later. Instead, contact your allergist's office to reschedule. The safety of your next dose depends on how long it has been since your last injection. If only a few days have passed, you may be able to continue with the planned dose. If several weeks have passed, your doctor will likely need to reduce the dose to prevent a reaction and then gradually build you back up. Consistency is key to both the safety and effectiveness of allergy immunotherapy.
There is no clinical evidence to suggest that Fraxinus Latifolia Whole causes weight gain. The extract consists of small amounts of proteins and glycerin, which do not have enough caloric content or metabolic impact to affect body weight. If you experience weight changes while on immunotherapy, they are likely due to other factors, such as lifestyle changes or other medications you may be taking (like oral corticosteroids for asthma). Always discuss any unexpected physical changes with your healthcare provider to identify the underlying cause.
Fraxinus Latifolia Whole can be taken alongside most common allergy medications like antihistamines and nasal steroids, but there are some critical exceptions. The most important interaction is with beta-blockers, which are often used for high blood pressure or heart conditions. Beta-blockers can make an allergic reaction much more dangerous and prevent epinephrine from working. You must also tell your doctor if you are taking antidepressants like MAOIs or TCAs. Always provide a full list of your medications to your allergist before starting treatment to ensure there are no dangerous interactions.
The concept of 'generic' vs. 'brand name' works differently for allergenic extracts. Fraxinus Latifolia Whole is a biological product produced by several different specialized laboratories (such as Greer, ALK, or Jubilant HollisterStier). While the extracts from different companies are similar, they are 'non-standardized,' meaning they are not exactly identical in potency. Your allergist will usually stick with one manufacturer's extract for your entire course of treatment to ensure consistency. Because these are biological extracts rather than synthetic chemicals, they are not referred to as generics in the traditional sense.